Published on
February 8, 2020
- 20:06 GMT
Adverum Biotechnologies Reports New Interim Data from Cohorts 1 and 2 of OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy ...
-- Robust efficacy with evidence of a dose response -- -- 6/6 patients rescue-injection-free in cohort 1, with 3 patients at 52 weeks -- -- 4/6 patients rescue-injection-free in cohort 2 (lower dose) at 24 weeks -- -- Company to host and webcast a …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Technology
...
